HCA Healthcare (HCA): Growth vs. Leverage Pressure
HCA Healthcare posted solid revenue and EPS growth, but its highly leveraged balance sheet and payer-mix headwinds keep the stock at Hold. The report sees durable demand and outpatient expansion offset by exchange coverage losses and balance sheet risk.
HCA Healthcare (HCA) is a Hold, earning an overall grade of B-. The stock looks reasonably supported by durable demand and solid operating execution, but our fair value is $460.59 and the balance sheet plus payer-mix pressure limit upside from here.
Thesis
HCA Healthcare (HCA) combines durable healthcare demand, a dense hospital and ambulatory network, and strong operating cash generation with a highly leveraged balance sheet and rising payer-mix pressure. The investment case rests on HCA's ability to convert volume growth, pricing, outpatient expansion, and cost initiatives into earnings growth while absorbing the $1.0 billion to $1.2 billion 2026 adjusted EBITDA headwind tied to health insurance exchange coverage losses.
The business has produced 8.7% year-over-year revenue growth and 11.6% diluted EPS growth in the second quarter of 2026. Same-facility admissions increased 2.5%, emergency room visits rose 3.6%, and revenue per equivalent admission increased 6.4%. Those figures show that demand and pricing remain productive even as elective surgeries and exchange-covered volumes weaken.
The balance sheet prevents a more aggressive rating. HCA carried $51.6 billion of debt and $1.0 billion of cash at June 30, 2026, while 2025 year-end equity was negative $2.8 billion and the current ratio was 0.83. The result is a Hold recommendation for a moderate-risk, medium-term investor, with the strongest entry case reserved for materially lower prices.
Company Overview
Founded in 1968 and headquartered in Nashville, Tennessee, HCA Healthcare operates hospitals, ambulatory surgery centers, emergency facilities, urgent care sites, imaging centers, rehabilitation facilities, physician practices, home health agencies, and hospice operations. The company employed approximately 230,000 people according to its corporate profile.
HCA's second-quarter 2026 materials described a network of 190 hospitals and approximately 2,600 ambulatory sites across 19 states and the United Kingdom. That footprint gives the company multiple points of contact with patients, from emergency care to inpatient treatment and outpatient procedures.
▌Common Questions
Frequently asked questions
+Is HCA stock a buy right now?
HCA is a Hold right now, not a Buy. The company is still growing revenue and earnings, but the report flags a highly leveraged balance sheet and payer-mix pressure that keep the risk/reward balanced.
+What is HCA's fair value?
HCA's fair value is $460.59. That estimate reflects strong operating momentum, including 8.7% revenue growth and 11.6% diluted EPS growth in Q2 2026, but it is tempered by $51.6 billion of debt, a 0.83 current ratio, and the expected 2026 EBITDA headwind from exchange coverage losses.
+Why is HCA rated Hold instead of Buy?
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
The latest quarter produced $20.23 billion of revenue, $1.70 billion of net income attributable to HCA, $7.62 of diluted EPS, and $4.03 billion of adjusted EBITDA. For 2025, annual revenue reached $75.60 billion and net income reached $6.78 billion.
Business Segment Deep Dive
The 2025 revenue mix shows HCA's economic exposure across payer and service categories. Managed care and other insurers generated $36.97 billion, or 50.5% of the supplied mix. Managed Medicare contributed $13.44 billion, or 18.4%, while traditional Medicare contributed $11.27 billion, or 15.4%.
Medicaid generated $5.91 billion, or 8.1%, and managed Medicaid generated $3.69 billion, or 5.0%. International revenue contributed $1.86 billion, or 2.5%. This mix makes reimbursement policy and commercial contracting central to HCA's earnings profile.
The second-quarter operating figures show different trends by care setting. Same-facility admissions increased 2.5% and equivalent admissions increased 2.7%, while inpatient surgeries declined 2.3% and outpatient surgeries declined 3.4%. Emergency room visits grew 3.6%, highlighting the relative strength of urgent and medically necessary care.
HCA also received a $400 million incremental net benefit from Medicaid supplemental payment programs in the quarter, including a $540 million benefit tied to the Florida program from October 1, 2024 through June 30, 2026. The 2026 guidance includes a $300 million to $500 million benefit from these programs.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
HCA's flagship offering is its integrated care network rather than a single medical product. The network links hospitals, emergency departments, surgery centers, diagnostic facilities, physician practices, and rehabilitation services. Its value is highest when the company captures a patient at one point of care and retains the related treatment flow across its system.
Emergency care is the strongest current service line. Management said emergency inpatient cases represented approximately two-thirds of inpatient surgeries and increased 2% year over year through the first six months of 2026. Cardiac procedures and rehabilitation volumes also helped drive demand improvements.
Elective care is the weak point. Management said elective inpatient surgery declined 6% in the first half of 2026, compared with a 2% decline in 2025. Outpatient surgery is predominantly elective, which exposes that network to affordability pressure and the loss of health insurance exchange coverage.
Innovation & Competitive Advantage
HCA's competitive advantage comes from scale, network density, centralized operations, and clinical data rather than traditional intellectual property. A 190-hospital platform can spread purchasing, technology, administrative, and workforce investments across a large revenue base.
Management's financial resiliency program includes digital transformation, global capabilities, workforce development, shared services, and artificial intelligence and machine learning initiatives. Same-facility cost per equivalent admission was essentially flat year over year in the second quarter after considering Medicaid supplemental payment programs, and improved 1.4% sequentially.
HCA has approved more than $7 billion of capital expenditures expected to come online over three years. The plan includes 1,000 to 1,200 additional inpatient beds and 250 to 300 outpatient facilities in the capital or acquisition pipeline. Management also reported 5% more sites of care in the second quarter than in the prior-year quarter.
Operations & Supply Chain
HCA's operating model requires sustained investment in hospitals, operating rooms, equipment, technology, and outpatient facilities. Second-quarter capital expenditures totaled $1.2 billion, and management maintained its 2026 capital expenditure range of $5.0 billion to $5.5 billion.
Operating cash flow reached $2.33 billion in the second quarter, down from $4.21 billion in the prior-year quarter. Management attributed the decline primarily to timing differences involving Florida Medicaid supplemental payments and the prior-year deferral of federal income tax payments.
Capital allocation remains active. HCA repurchased $2.1 billion of shares and paid $171 million in dividends during the quarter. The company also reported professional fees up 8.5% on a same-facility basis, while total cash cost per adjusted admission was flat to slightly higher year over year.
Market Analysis
The underlying hospital market is large and expanding. CMS reported $1.63 trillion of U.S. hospital expenditures in 2024, up 8.9% year over year. CMS also projects national health expenditure growth of 5.4% annually from 2025 through 2034, compared with projected GDP growth of 4.1%.
The care setting is changing as procedures move from inpatient hospitals to ambulatory surgery centers, urgent care facilities, and physician-owned sites. Market research cited in the supplied industry material projects U.S. ambulatory care center growth of 6.48% annually through 2031 and U.S. ambulatory surgery center growth of approximately 6.3% from 2026 through 2033.
HCA's long-term demand assumption is 2% to 3%, supported by population growth in Florida, Texas, Utah, Nevada, South Carolina, Georgia, and Tennessee. The company's 2,600-site ambulatory footprint gives it a direct vehicle for participating in the site-of-care shift.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
HCA serves patients whose payment sources include managed care and other insurers, Medicare, managed Medicare, Medicaid, managed Medicaid, and health insurance exchanges. The 2025 mix supplied for the company shows managed care and other insurers as the largest category at 50.5% of revenue.
The most important customer shift in 2026 involved exchange coverage. Adjusted admissions from formerly exchange-covered patients declined 15% in the second quarter. Management said those patients migrated almost one-for-one into the uninsured population, and that the migration represented approximately 80% of uninsured volume growth.
Insured volumes excluding exchanges increased 3.2% in the second quarter and 2.2% year to date. Emergency care remained resilient, while elective procedures faced affordability pressure and lower demand. This split makes HCA's volume growth durable in urgent care but more cyclical in elective care.
Competitive Landscape
HCA competes with Tenet Healthcare (THC), Universal Health Services (UHS), Community Health Systems (CYH), nonprofit health systems, regional hospitals, physician groups, ambulatory surgery centers, urgent care operators, and insurers that influence patient steering and reimbursement.
HCA's 190 hospitals and approximately 2,600 ambulatory sites provide greater network density than a typical regional operator. The network supports physician relationships, payer negotiations, patient routing, purchasing scale, and investment in specialized services.
Management's midyear market-share review described HCA's competitive positioning as stable to growing on a net basis. The company reported gains in many markets, with some markets flat and some modestly lower. The $7 billion investment plan is aimed at adding beds, hospitals, outpatient facilities, technology, and physician capacity.
Macro & Geopolitical Landscape
Healthcare policy is the dominant macro variable for HCA in 2026. Enhanced premium tax credits expired at the end of 2025, and HCA's second-quarter experience showed a 15% decline in exchange-related admissions and a near one-for-one shift into uninsured care.
Medicaid policy provides an offset but also creates timing risk. HCA recognized a $400 million second-quarter benefit from supplemental payment programs, while its updated 2026 guidance implies a $100 million to $300 million headwind in the second half because prior-year approvals and retroactive payments exceeded the incremental Florida benefit.
The company also identifies inflation, tariffs, trade policies, Medicare inpatient rule changes, and broader healthcare policy developments as guidance variables. Management said Medicare rule changes shifted some procedures from inpatient to outpatient settings, which makes HCA's ambulatory expansion strategically important.
Balance Sheet Health
▌Premium Members Only
HCA carried $51.6 billion of debt against just $1.0 billion of cash at June 30, 2026, with a current ratio of 0.83 and negative $2.8 billion of 2025 year-end equity.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
2026 guidance still includes a $1.0 billion to $1.2 billion adjusted EBITDA headwind from exchange coverage losses, partly offset by a $300 million to $500 million Medicaid supplemental benefit.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
The report’s fair value framework lands at $460.59, reflecting solid earnings growth but a valuation that is capped by leverage and reimbursement risk.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
HCA Healthcare remains a high-quality operator with a large network, strong emergency demand, improving operating efficiency, and a clear outpatient expansion plan. Revenue growth reached 8.7% in the second quarter, diluted EPS growth reached 11.6%, and management expects $77.0 billion to $79.5 billion of 2026 revenue.
The counterweight is material. Exchange-related coverage losses, lower elective surgery volumes, a $51.55 billion debt balance, negative equity, and a 0.83 current ratio keep HCA from earning an aggressive rating. The $460.59 Hold level reflects a sound franchise priced against real policy and financial risks.
For a medium-term investor, HCA is a disciplined watchlist holding rather than a balance-sheet-light compounder. The strongest investment opportunity appears at the $390 Buy level or below, where the company's emergency-care resilience, network expansion, and forward EPS trajectory would offer more room for execution risk.
HCA earns a Hold because the business is executing well operationally, but the balance sheet is stretched and reimbursement mix is becoming less favorable. The report specifically points to $51.6 billion of debt, negative equity, and a $1.0 billion to $1.2 billion 2026 EBITDA headwind as the main reasons upside is limited.
+What are the biggest risks to HCA stock?
The biggest risks are leverage, payer-mix pressure, and weaker elective surgery volumes. HCA also faces a $1.0 billion to $1.2 billion adjusted EBITDA headwind in 2026 from health insurance exchange coverage losses, which could offset otherwise healthy demand trends.
+How is HCA performing operationally?
Operationally, HCA is performing well, with same-facility admissions up 2.5%, emergency room visits up 3.6%, and revenue per equivalent admission up 6.4% in Q2 2026. The weakness is concentrated in elective care, where inpatient surgeries fell 6% in the first half of 2026.
▌For Active Investors
Want Reports Like This on Any Stock?
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.